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Abstract 
Background/Introduction: Pharmacist teleconsultations, combined with home drug delivery or mail-order 
pharmacy (MOP), can help hospital outpatients with difficulties accessing treatment. The objectives of this 
study are to describe a teleconsultation protocol and to evaluate clinical, economic, and patient-perceived 
quality results. 
Materials and Methods: A cohort observational study was carried out for 3 years on HIV outpatients. 
Clinical variables were adherence, plasma HIV-RNA, and CD4+ levels. A pharmacoeconomic analysis was 
carried out through a cost-minimization study. Patient-perceived quality was assessed through a satisfaction 
survey. Simple random sampling was performed for 95% safety, accuracy ±1%, and losses ±20%. 
Results: The 38 participants (sample size) consisted of 82% male patients, aged 44.7 ± 8.4 years. There were 
854 teleconsultations and 100% treatment adherence. All HIV outpatients kept virally suppressed (p = 1.00) 
and maintained a controlled immunological level (p = 0.87). The economic evaluation revealed 137 ± 23 € 
patient/year costs-saved and 18.5 ± 7.2 h/patient/year working time gained. Patient-perceived quality average 
score was >9.4 out of 10 in all items; the most valued factors were the saving of direct costs and 
reconciliation with work commitments (45%) and the least valued attributes were making the payment for the 
shipment and having to adjust to a telephone appointment (41%). 
Discussion/Conclusions: A teleconsultation protocol associated with home antiretrovirals delivery or MOP 
obtains a high degree of satisfaction from the HIV hospital outpatients receiving treatment, without 
repercussions on the therapeutic objectives and with the saving of important direct costs for the patient and 
indirect costs in relation to labor productivity. 
Keywords: Teleconsultation, telepharmacy, HIV, antiretroviral agents, home drug delivery, mail-order 
pharmacy, pharmaceutical care, telemedicine 
  
Introduction  
The World Health Organization (WHO) defines telemedicine as the provision of health services, 
where distance is a critical factor, by any health professional through the use of information and 
communication technologies for the exchange of valid information for diagnosis, treatment and 
prevention of diseases and injuries, research and evaluation, and the permanent education of 
healthcare providers, all in the interest of improving the health of individuals and their 
communities.1 Telepharmacy is, therefore, to be considered a part of telemedicine and has been 
defined as a method used in pharmaceutical practice in which a pharmacist uses communication 
technologies to provide patient care services or to supervise pharmacy activities that may include, 
but are not limited to, the validation and monitoring of treatments, dispensing, the validation of the 
preparation of medications, providing information and advice to patients, clinical consultations, 
evaluation of results, support for decisionmaking, and providing information on medications.2  
 
In healthcare systems around the world, home drug delivery (HDD) in Europe, called mail-order 
pharmacy (MOP) in the United States of America, has been used alongside telepharmacy for the 
provision of pharmacological treatments at home or the workplace. Both HDD and MOP facilitate 
better access to medication, especially in rural regions or those involving great geographical 
dispersion, and those that have other difficulties of access in relation to pharmaceutical care, but 
differ mainly in that MOP is performed from community pharmacies and HDD from hospital 
pharmacy services (HPSs) for certain medications. HDD has produced very good clinical results in 
terms of both its level of efficiency and its therapeutic safety3–7; also, MOP has showed good 
clinical results in terms of adherence to treatment in chronic diseases, mainly in diabetes.8–13  
 
In addition to improving accessibility to treatment, HDD/ MOP prevents the situation whereby the 
patient has to travel periodically to the community pharmacy or the hospital pharmacy, and this 
promotes work and family reconciliation, decreases direct and indirect costs both from the 
patient’s and from the social perspective and increases overall satisfaction with the health system 
that provides the service. These aspects are necessary to include in the evaluation of this healthcare 
procedure; however, they have been evaluated in very few studies14–16 or have been analyzed from 
the perspective of publics or private pharmacy benefit management plans (Medicare Part D, 
Medicaid, U.S. Department of Defense Healthcare Plan, Retirement Systems, etc.).17–20  
 
There are no published studies that evaluate any of these aspects in Spain, where pharmaceutical 
care (PhC) for outpatients using HPSs is required for medicines classified as ‘‘hospital diagnosis-
HD’’ or ‘‘hospital use-H.’’ These medications cannot be dispensed at community pharmacies and 
should only be dispensed at hospital pharmacy, with a monthly or bimonthly periodicity. Current 
regional regulations establish, for community pharmacies, that HDD is authorized for, among 
other patients, stable chronically ill outpatients, in special circumstances, with a guaranteed 
medical prescription and with prior dispensing of that same medication; so HDD from HPS could 
be applied to outpatients treated through pharmaceutical telecare with HD-medicines or H-
medicines. 
 
In our hospital, pharmaceutical care to outpatients with HD-medicines or H-medicines is provided 
by pharmacists specialized in pathologies or specific therapeutic areas, in monographic 
consultations with a very high degree of outpatient satisfaction.21 The health area covered by our 
hospital has a highly dispersed population (550,000 inhabitants, largely rural, aging, and with 
limited access by public or private means of transport from certain remote locations). The 
pharmacists responsible for pharmaceutical care to outpatients in our hospital, considering this, 
assess patients’ suitability for HDD and pharmaceutical telecare, and promote telepharmacy within 
the strategic plan of the Pharmacy Service. To this end, they have approved and implemented a 
telepharmacy protocol based on teleconsultation in relation to pharmaceutical care (TcPhC) with 
HDD for clinically stable outpatients with difficulties accessing treatment for various reasons 
(labor, economic, family, etc.). These patients may currently include solid organ transplant 
patients, HIV patients, patients with arthropathies, and patients with pulmonary or neurological 
diseases. It is interesting, therefore, to investigate what repercussions TcPhC–HDD has at various 
levels, so that, according to the results of this examination, health managers can make decisions 
based on evidence regarding this aspect of telepharmacy. More specifically, in the field of persons 
living with HIV on antiretroviral therapy, a recent survey of pharmacists working in different 
settings revealed the need of more research about the impact of MOP on adherence or health 
outcomes, the skills to overcome the lack of face-toface consultations, or when to switch patients 
to HDD or MOP.22  
 
In accordance with that mentioned, the objectives of this study are to describe HIV patient 
candidates for the TcPhC– HDD protocol, the implementation phases required, and the care circuit 
and subsequently to evaluate the clinical, economic, and patient-perceived quality results 
postimplementation.  
Materials and Methods  
TCPHC–HDD protocol  
The TcPhC–HDD protocol for HIV outpatients was coordinated between the hospital pharmacists 
and the physicians responsible for the Hospital Immunodeficiency Unit (HIU) and the inclusion 
and exclusion criteria for the candidate patients were established. The inclusion criteria were as 
follows: adult HIV outpatients receiving antiretroviral treatment (ART); at least 6 months of 
follow-up in the HIU and HPS before inclusion in the protocol; stable patients with chronic 
controlled infection objectified by two negative viral loads in consecutive determinations during at 
least the past 6 months; and 100% adherence to ART (according to medical and pharmaceutical 
criteria registered in the course of the electronic clinical medical record). Exclusion criteria were 
as follows: patients with ART change motivated by virological failure or the development of 
adverse effects (until resolution of the reason for change); breach of a previous appointment during 
the last year in outpatient hospital pharmacy or medical clinic without scheduling a replacement; 
concomitant treatment with other HD-medicines or H-medicines that require face-to-face 
consultation in HPS; and appointments scheduled at the hospital during the dispensing period 
allowed by the ‘‘single clinical act’’ (administrative procedure of scheduling several appointments 
in different outpatient hospital clinics on the same day).  
 
Subsequently, in collaboration with the hospital agents involved (pharmacist, physicians, the 
Pharmacy Service Manager, and the Hospital Manager and Hospital Medical Director), the 
document ‘‘TcPhC–HDD Work Instruction’’ was drafted and included within the quality 
certification program of the HPS, the Patient Request and Informed Consent Form was designed 
to facilitate the patients’ access to this protocol and submitted for the approval of the Hospital 
Medical Director. The document ‘‘TcPhC–HDD Work Instruction’’ established the following 
assistance circuit:  
 
(1) Patient inclusion: pharmacist gives a detailed explanation to the patient of the TcPhC–
HDD protocol and, if the patient agrees, she/he signs the ‘‘Patient Request and Informed 
Consent Form.’’  
(2) Patient assignment to the Teleconsultation (2.2FT) provision in the agenda of the 
monographic consultation for the pharmaceutical care of HIV patients.  
(3) Bi-monthly telematic consultation after appointment and the conducting of clinical 
interviews according to the same standard procedure for pharmaceutical care, which is in 
effect for face-to-face consultations (mainly treatment assessment, clinical variables 
monitoring, adherence evaluation, pharmacological interactions, and adverse effects 
monitoring). Since hospital extranet does not absolutely guarantee the 
privacy/confidentiality of the communication with outpatients, they receive telematic 
consultation by telephone call wherever they are (home, workplace, etc.). Therefore, no 
special technical requirements are needed to engage in the program.  
(4) Documentation of the clinical interviews and the pharmaceutical care provided in the 
course of the clinical pharmacy activity, as indicated by the electronic medical record.  
(5) Electronic account of the quantity of dispensed units from the pharmacy service drug 
stock.  
(6) Preparation and packing of medication by the pharmacy technician of the HPS.  
(7) Coordination of HDD with the distribution company as arranged by the hospital through 
the HPS administrator.  
(8) Home reception of the medicine within 24 h and patient payment of transportation costs. 
Study design  
This consisted of a pre–post cohort observational retrospective study on interventions carried out 
on patients included in the TcPhC–HDD protocol at some time from July 2014 to July 2017. The 
specific intervention looked at by this study is patient inclusion in the TcPhC–HDD protocol in 
any of the face-to-face pharmaceutical care consultations carried out with the patient during the 
study period.  
 
Three types of variables were evaluated: clinical, pharmacoeconomic, and in relation to patient-
perceived quality. Three clinical variables were included: ART patient adherence, plasma HIV-
RNA, and CD4+ levels. Two pharmacoeconomic variables were included: (1) direct costs avoided 
from the patient’s perspective (cost-minimization study assuming the same final clinical results—
costs of public or private transportation that the patient would have had to incur to go to the HPS 
consultation less the costs actually paid by the patient to the company responsible for drug home 
delivery) and (2) indirect costs (lost work hours avoided by the avoidance of the need to travel the 
hospital in active patients). Finally, patient-perceived quality was assessed through eight variables 
extracted from each household and an anonymous Teleconsultation satisfaction survey, which was 





Fig. 1. Teleconsultation pharmaceutical care—HDD satisfaction survey. HPS, Hospital Pharmacy Service; 
TcPhC-HDD, teleconsultation of pharmaceutical care with home drug delivery  
Statistical analysis  
Simple random sampling was performed among patients involved in the TcPhC–HDD protocol for 
95.0% safety, accuracy ±1.0%, and losses ±20.0%. Quantitative variables are expressed here as 
means ±standard deviation and qualitative variables as percentages with a confidence interval of 
95%. Statistical significance was calculated with the Fisher exact test and the Mann–Whitney test. 
Results were considered statistically significant when their p-value was <0.05. Statistical analysis 
was carried out using the Epidat 3.1 program. 
Ethics  
Access to the patient’s clinical history data was based on ‘‘Patropresvih Study,’’ as classified by 
the National Health Authorities in 2014 as a ‘‘Post-authorization study with other aims than the 
prospective follow-up’’ and approved by the Regional Clinical Research Ethics Committee. 
Previously, patients had already signed a consent to participate in the TcPhC–HDD protocol, and 
had given verbal consent to participation in this study.  
Results  
Of the 1,119 HIV patients on ART at our institution, 81 patients were selected for inclusion in the 
TcPhC–HDD protocol for 3 years, during which 354 face-to-face consultations and 854 
teleconsultations associated with home drug deliveries were carried out. Of these 81 patients, 38 
constituted the sample analyzed according to the statistical design applied. All patients had a 100% 
adherence to treatment. Table 1 shows the main characteristics of the study population.  
Table 1. Characteristics of the Study Population  
  
Demographic characteristics  
Age, years (mean ± SD)  44.7 ± 8.4 
Gender, men  81.6% 
TcPhC-HDD-related variables  
Employment situation  
Labor-active patients  78.9% 
Unemployed  13.2% 
Pensioner  7.9% 
Means of transport to HPS  
Private (car)  78.2% 
Public (bus or train)  21.8% 
Patient transport payment  
Self-payment  93.3% 
Public aids  6.7% 
Time to arrive and return to face-to-face HPS appointment from 
home or workplace, minutes (mean ± SD) 
145.8 ± 122.2 
Way of TcPhC-HDD knowledge  
Pharmacist proposal  60.5% 
Patient’s request  21.1% 
Nurse/physician proposal  13.2% 
Other patients  5.2% 
Patient’s beliefs about who has established TcPhC-HDD  
Doesn’t know  57.9% 
Hospital pharmacy service  26.3% 
Hospital authorities  10.5% 
Regional health service  5.3% 
Best valued factor of TcPhC±HDD (multiple answer)  
Savings on travel expenses  45.8% 
Labor reconciliation  45.8% 
Family reconciliation  31.6% 
Improvement in privacy and confidentiality  21.5% 
Others  5.3% 
Worst factor of TcPhC-HDD (multiple answer)  
Having to pay transportation expenses  41.7% 
Prior appointment of the telephone call  41.0% 
Telephone communication  2.6% 
Lack of privacy in deliveries  2.6% 
Others  0% 
Preference of face-to-face consultations and exit TcPhC-HDD  
No  100% 
Yes  0% 
Time on TcPhC-HDD protocol, months (median)  19.9 




HPS, hospital pharmacy service; SD, standard deviation; TcPhC±HDD, teleconsultation of pharmaceutical 
care with home drug delivery 
At the clinical level, ART effectiveness variables showed that 100% of the patients maintained an 
HIV viral load of undetectable (p = 1.00) and an immunological level (CD4+ = 658 ± 224/µL; p = 
0.87), after an average of 1 year of the pharmaceutical follow-up protocol. The economic 
evaluation of the variables related to direct and indirect costs revealed that the patient/year costs-
saved were 137±23 € and the patient/year working time gained was 18.5±7.2 h.  
 
The satisfaction survey indicated that the factors most valued by the outpatients were the saving of 
direct costs (45.8%, 95% CI 30.7–61.0%) and labor time recovery (45.8%, 95% CI 30.7– 61.0%) 
and the least valued factors were having to make the payment for the shipment (41.7%, 95% CI 
26.7–56.6%) and having to adjust to a telephone appointment (41%). Figure 2 shows the results 





Fig. 2. Results of teleconsultation of pharmaceutical care—HDD satisfaction survey. 
Discussion  
The introduction of telepharmacy as a line of action for health services allows patients to have 
access to pharmaceutical healthcare services remotely through communication technologies with a 
wide range of services included, ranging from validation or pharmaceutical monitoring, 
information about medicines, health education, and medication reconciliation services to home 
delivery.23,24 Within this process, the TcPhC–HDD pharmacy protocol proposed in our HPS aimed 
to allow access to pharmaceutical care for HIV patients with access difficulties as regards the 
hospital, either because of work, family, economic, or geographical dispersion reasons. This was 
implemented to maintain the therapeutic goal of ART, that is, the negativization of HIV load and 
the level of immunocompetence achieved. Assessing the baseline characteristics of the patients 
included in the study (young adult labor-active population using self-payment private means of 
transport for their access to the HPS) and the best valued items shown by the patients in the 
satisfaction survey (saving on travel expenses and labor/family reconciliation), we consider that 
stable HIV patient is an excellent target population since it meets the criteria that justify the 
implementation of this telecare protocol.  
 
At a clinical level, the results of our study have shown that the TcPhC–HDD protocol has not 
caused statistically or clinically significant decreases in CD4+ lymphocyte levels, and, in addition, 
it has maintained virally suppressed all patients included in the study. This is an essential point for 
the positive evaluation of the program, since the value of HIVRNA is the main variable of 
effectiveness of ART.25 Very few clinical studies have evaluated the impact of telepharmacy on 
patients monitored through these technologies. Some recent studies have demonstrated the validity 
of this type of pharmaceutical care on asthma, diabetes, and patients at hospital discharge.26–30 
However, very few studies have analyzed the influence of telepharmacy on the clinical outcome of 
HIV patients receiving ART or the evaluation has been limited to the influence of MOP for 
improving medication adherence to ART.31 The first study that evaluated the impact of 
telepharmacy for HIV patients receiving ART was carried out in Spain with regard to the 
‘‘HospitalVirtual’’ experience of the hospital clinic of Barcelona; this was encompassed within a 
telemedicine computer platform. It was demonstrated through a randomized clinical trial that 
telemedicine is a safe tool for home care of chronic HIV patients and should be considered as an 
appropriate support service for the management of chronic HIV infection.32–34 More recently, 
Castellino et al.35 showed that home delivery did not generate negative results in terms of 
adherence to ART by HIV patients, nor on viral load of HIV or on CD4+ lymphocytes; this is in 
line with our study, which seems to corroborate these previous results of the Barcelona group.  
 
Another important issue related to telepharmacy is the promotion of the accessibility of 
pharmaceutical care and pharmacological treatments to outpatients. This is especially, although 
not exclusively, significant where patients live in rural populations, in very dispersed population 
areas or with difficulties in accessing face-to-face healthcare from their areas of residence or work. 
Based on this idea, a potential disparity between rural and urban patients’ access to clinical 
pharmacy services has been identified and telepharmacy could decrease this disparity.36,37 In fact, 
some studies have shown the benefits of telepharmacy at this level.38,39 In line with these results, 
our study has revealed that the average time spent attending the HPS outpatient clinic is almost 2.5 
hours, which confirms the enormous distance and difficulties in accessing for HIV outpatients 
from home or workplace. In addition, one of the aspects most valued by HIV outpatients included 
in TcPhC–HDD is precisely the work–life reconciliation, especially considering that 80% of them 
are labor active.  
 
The third aspect to consider is the economic one. No study has previously evaluated the economic 
impact of HDD or MOP from the HIV outpatient perspective; most of the published studies in 
other chronic pathologies have been carried out from the perspective of the service provider or 
payer and suggest that these drug-dispensing systems do not provide a clear economic benefit11,40 
or result in a marginal opportunity cost.8,41–44 Conversely, our study results show that the travel 
every month or every 2 months to the HPS for face-to-face consultation and drug dispensing 
represents an important expense that the patient assumes and is the cause of a loss of relevant 
productivity throughout the year and demonstrate a clear benefit at this level; unfortunately, our 
results cannot be compared with those of other studies, since these exact parameters have not been 
previously analyzed.  
 
Finally, it is worth highlighting that in accordance with other research studies,6 excellent results 
were obtained through the anonymous survey of hospital outpatient satisfaction in the protocol; 
this showed a high perceived quality (with an overall result of 9.7 points out of 10), both at the 
organizational level and in terms of the functioning of the system (items 1–4) and at the 
pharmaceutical care level (items 5–7). However, some aspects of the protocol could be improved, 
as stated by the patients, in relation to telephone call appointment and delivery payments. In 
addition, none of the surveyed patients felt they would prefer to abandon the TcPhC–HDD 
protocol and return to prior types of consultations. In our opinion, this high satisfaction rate is 
motivated because our protocol hospital includes not only the periodic sending of medication but 
also the maintenance of teleconsultation of pharmaceutical care, as patients (HIV or not) have 
claimed in different studies.45,46  
 
From our point of view, the main limitation of this study (and, therefore, of the extrapolation of 
results to the entire population of HIV outpatients treated by the pharmacy service of our hospital) 
is that the TcPhC–HDD protocol currently includes HIV patients who have previously shown be 
adherent to treatment and clinically controlled. This could have led to a results bias. However, we 
considered it necessary to explore first using this type of stable patient whether or not the protocol 
causes negative results with regard to their clinical situation. Thus, in later phases of 
implementation (and given the excellent results obtained), we can extend our researches to other 
HIV patients and assess in a further study whether, as a result of better access to treatment, other 
patients could actually improve their clinical results. In contrast, our study has clear strengths 
taking into account the HIV outpatient perspective, since it brings new findings not previously 
published in relation to the economic benefit of pharmacist teleconsultation with HDD/MOP and, 
above all, excellent results are presented for the first time on the clinical variables that define the 
progression of HIV disease and patient survival.  
  
In summary, TcPhC–HDD obtains a high degree of satisfaction from HIV hospital outpatients 
receiving ART and has no negative repercussion on the therapeutic objectives in terms of HIV 
plasma viral load or CD4+ lymphocytes plasma level, and in addition saves on direct costs, which 
are important for the patient and on indirect costs with regard to labor productivity. We consider 
that we are in a position to expand the inclusion criteria for HIV patients and analyze the results 
then produced.  
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